ArticleNanoscale advances2026
ZnO@PDA@Ag nanocomposite-mediated delivery of 9-bromonoscapine, an anticancer agent, for enhanced lung cancer therapy.
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer continues to be a global threat to mankind responsible for numerous mortalities across international boundaries, underscoring the pressing need for improved therapeutic alternatives. Recently, multifunctional nanocomposites have been developed as promising platforms for anticancer therapy, offering targeted drug delivery and better intrinsic therapeutic properties owing to enhanced solubility, stability, and targeted release of hydrophobic drugs. In the present work, a biocompatible silver-modified PDA-coated zinc oxide nanocomposite was synthesized and loaded with the hydrophobic anticancer drug '9-bromonoscapine' (9-Br-Nos) to develop a 'ZnO@PDA@Ag@9-Br-Nos' nanocomposite for lung cancer treatment. The characterization of the nanocomposite was done using techniques namely DLS, TEM, zeta potential measurement, FESEM-EDX, TGA, PXRD, and FT-IR, which confirmed the nanocomposite's size, charge, stability, and functional integrity. Moreover, drug loading and release were quantified
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.